Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

NEW DRUGS

FDA Approved Fyarro for Malignant Perivascular Epithelioid-Cell Tumor

JHOP - December 2021 Vol 11, No 6 - FDA Oncology Update
Download PDF

On November 22, 2021, the FDA approved sirolimus protein-bound particles for injectable suspension (albumin-bound [Fyarro; Aadi Bioscience]) for adults with locally advanced, unresectable or metastatic malignant perivascular epithelioid-cell tumor (PEComa), a rare type of mesenchymal tumors that can occur in any body site.

This FDA approval was based on a multicenter, single-arm clinical trial of 31 patients with locally advanced, unresectable or metastatic malignant PEComa. Patients received sirolimus protein-bound particles on days 1 and 8 of each 21-day cycle, until disease progression or unacceptable adverse events.

The main end points were overall response rate (ORR) and duration of response (DOR). The ORR was 39% (95% confidence interval [CI], 22%-58%), which included 2 patients with complete responses. The median DOR was not reached (95% CI, 6.5 months-not estimable). Of the 39% of patients who had a response, 67% had a response lasting >12 months, and 58% had a response lasting >24 months.

The most common (≥30%) adverse events were stomatitis, fatigue, rash, infection, nausea, edema, diarrhea, musculoskeletal pain, decreased weight, decreased appetite, cough, vomiting, and dysgeusia. The most common (≥6%) grade 3 or 4 laboratory abnormalities were decreased lymphocytes, increased glucose, decreased potassium, decreased phosphate, decreased hemoglobin, and increased lipase.

The recommended dosage is 100 mg/m2, administered as an intravenous infusion over 30 minutes on days 1 and 8 of each 21-day cycle, until disease progression or unacceptable side effects.

Related Items
Cytalux, a Novel Imaging Agent, FDA Approved for Diagnosing Inoperable Ovarian Cancer Lesions
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Oral Scemblix FDA Approved for Patients with Ph-Positive Chronic Myeloid Leukemia
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Darzalex Faspro, Kyprolis, and Dexamethasone a New Combination FDA Approved for Multiple Myeloma
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Keytruda Now FDA Approved for Adjuvant Treatment of Renal-Cell Carcinoma
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Tecentriq First Immunotherapy FDA Approved for Adjuvant Treatment of Early-Stage Non–Small-Cell Lung Cancer
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Keytruda plus Chemotherapy FDA Approved for First-Line Treatment of Cervical Cancer
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Verzenio with Endocrine Therapy FDA Approved for Adjuvant Treatment of Early Breast Cancer
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Tecartus FDA Approved for Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Tivdak First Antibody–Drug Conjugate FDA Approved for Recurrent or Metastatic Cervical Cancer
JHOP - October 2021 Vol 11, No 5 published on October 14, 2021 in FDA Oncology Update
Exkivity Novel Oral Targeted Therapy Approved for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
JHOP - October 2021 Vol 11, No 5 published on October 14, 2021 in FDA Oncology Update
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.